# China NMPA Product Recall - Disposable human venous blood collection container

Source: https://www.globalkeysolutions.net/records/china_product_recall/liuyang-sanli-medical-technology-development-co-ltd/75003295-7f7e-4a96-badf-c645453e39cb/
Source feed: China

> China NMPA product recall for Disposable human venous blood collection container by Liuyang Sanli Medical Technology Development Co., Ltd. published September 21, 2020. Recall level: Level 3. Liuyang Sanli Medical Technology Development Co., Ltd. initiated a Class III voluntary recall of its

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Liuyang Sanli Medical Technology Development Co., Ltd. has voluntarily recalled its disposable human venous blood collection containers.
- Company Name: Liuyang Sanli Medical Technology Development Co., Ltd.
- Publication Date: 2020-09-21
- Product Name: Disposable human venous blood collection container
- Recall Level: Level 3
- Recall Reason: The purity of the additives in the product was insufficient, resulting in blood clotting after blood collection.
- Discovering Company: Liuyang Sanli Medical Technology Development Co., Ltd.
- Manufacturing Company: Liuyang Sanli Medical Technology Development Co., Ltd.
- Summary: Liuyang Sanli Medical Technology Development Co., Ltd. initiated a Class III voluntary recall of its Disposable Human Venous Blood Sample Collection Containers under the oversight of China's National Medical Products Administration (NMPA). The recall, reported on September 1 and 16, 2020, and publicly announced on September 21, 2020, addresses a critical quality deficiency: insufficient purity of additives in the product tubes. This issue, affecting specific batches such as 181004, 191002, and 191211 of Sodium Citrate 9:1 2ml containers, led to blood clotting after sample collection, rendering the devices unsuitable for their intended use in medical laboratories. The recall impacts significant quantities, including 860,000 units in Liaoning Province, 720,000 units in Inner Mongolia and Guizhou Province, and 360,000 units in Hunan Province. As required actions, the company established a recall leadership team, with the Marketing Department tasked with notifying distributors and users via multiple communication channels. Recalled products are managed in a dedicated warehouse, with unfit items subject to destruction under drug regulatory authority supervision. Products approved after quality evaluation and regulatory consent may be reintroduced.

Company: https://www.globalkeysolutions.net/companies/liuyang-sanli-medical-technology-development-co-ltd/25012e3f-dab9-40eb-a4b5-b11213e25b03/